Hypomethylating drugs convert HA-1 negative solid tumors into targets for stem cell based immunotherapy

Blood

Volumn 113, Issue 12, 2009, Pages 2715-2722

  Hambach, Lothar ^a   Ling, Kam Wing ^a   Pool, Jos ^a   Aghai, Zohara ^a   Blokland, Els ^a   Tanke, Hans J ^a   Bruijn, Jan A ^a   Halfwerk, Hans ^b   Van Boven, Hester ^b   Wieles, Brigitte ^a   Goulmy, Els ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; HISTONE; TRICHOSTATIN A;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEACETYLATION; DNA METHYLATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; GENE; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HA 1 GENE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; SENSITIZATION; SOLID TUMOR; STEM CELL TRANSPLANTATION; TUMOR CELL; TUMOR CELL LINE;

EID: 63849084718     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-158956     Document Type: Article

References (43)

1. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88:1501-1508.
2. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood. 2002;99:4234-4236.
3. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
4. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr Opin Immunol. 2005;17:202-210.
5. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol. 1996;8:75-81.
6. de Bueger M, Bakker A, van Rood J, van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens: ubiquitous versus restricted tissue distribution indicated heterogenity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol. 1992;149:1788-1794.
7. Dickinson A, Wang X, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med. 2002;8:410-414.
8. Klein C, Wilke M, Pool J, et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J Exp Med. 2002;196:359-368.
9. Fuji N, Hiraki A, Ikeda K, et al. Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. Transplantation. 2002;73:1137-1141.
10. Tykodi S, Warren E, Thompson J, et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res. 2004;10:7799-7811.
11. Hambach L, Vermeij M, Buser A, et al. Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. Blood. 2008;112:1844-1852.
12. den Haan J, Meadows L, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279:1054-1057.
13. Wilke M, Pool J, den Haan J, Goulmy E. Genomic Identification of the minor histocompatibility antigen HA-1 locus by allele-specific PCR. Tissue Antigens. 1998;52:312-317.
14. Spierings E, Hendriks M, Absi L, et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet. 2007;3:e103.
15. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science. 2001;293:1068-1070.
16. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8:286-298.
17. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457-463.
18. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37-50.
19. Sigalotti L, Fratta E, Coral S, et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res. 2004;64:9167-9171.
20. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. Epigenetic targets for immune intervention in human malignancies. Oncogene. 2003;22:6484-6488.
21. Guo ZS, Hong JA, Irvine KR, et al. De novo induction of a cancer/testis antigen by 5-aza-2′- deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 2006;66:1105-1113.
22. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res. 2008;14:3283-3290.
23. Serrano A, Tanzarella S, Lionello I, et al. Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidinetreatment. Int J Cancer. 2001;94:243-251.
24. Fonsatti E, Nicolay HJ, Sigalotti L, et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′- deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res. 2007;13:3333-3338.
25. Takai N, Kawamata N, Walsh CS, et al. Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res. 2005;3:261-269.
26. Spierings E, Drabbels J, Hendriks M, et al. Auniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications. PLoS ONE. 2006;1:e42.
27. Mutis T, Verdijk R, Schrama E, et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93:2336-2341.
28. Spierings E, Vermeulen C, Vogt M, et al. Identification of HLA class II-restricted H-Y specific T helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet. 2003;362:590-591.
29. Nagase T, Seki N, Ishikawa K, et al. Prediction of the coding sequences of unidentified human genes, VI: The coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of cDNA clones from cell line KG-1 and brain. DNA Res. 1996;3:321-354.
30. Kaminski WE, Piehler A, Schmitz G. Genomic organization of the human cholesterol-responsive ABC transporter ABCA7: tandem linkage with the minor histocompatibility antigen HA-1 gene. Biochem Biophys Res Commun. 2000;278:782-789.
31. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA. 2002;99:3740-3745.
32. Takai D, Jones PA. The CpG island searcher: a new WWW resource. In Silico Biol. 2003;3:235-240.
33. Wieles B, Pool J, Wilke M, et al. The diallelic locus encoding the minor histocompatibility antigen HA-1 is evolutionarily conserved. Tissue Antigens. 2006;68:62-65.
34. Hinshelwood RA, Huschtscha LI, Melki J, et al. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis. Cancer Res. 2007;67:11517-11527.
35. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res. 2002;62:6456-6461.
36. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635-1640.
37. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-57.
38. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol. 2008;20:705-710.
39. Aparicio A, Eads CA, Leong LA, et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol. 2003;51:231-239.
40. Samlowski WE, Leachman SA, Wade M, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol. 2005;23:3897-3905.
41. Bast R, Lyer R, Hu W, et al. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer [abstract]. J Clin Oncol. 2008;26:Abstract 3500.
42. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res. 2006;12:5777-5785.
43. Coral S, Sigalotti L, Gasparollo A, et al. Prolonged up-regulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J Immunother. 1999;22:16-24.